Matched odds ratios of peripheral neuropathy associated with exposure to each lipid lowering drug one year before the index date. Province of Varese, Italy, 1997–1999
| Cases | Controls | Unadjusted | Adjusted | |||
|---|---|---|---|---|---|---|
| Number (%) | Number (%) | OR† | (95% CI)† | OR† | (95% CI)† | |
| †Odds ratios, and 95% confidence intervals, estimated including exposure to each lipid lowering drug as covariate in a model of conditional logistic regression. Estimates are unadjusted and adjusted for the presence of thyroid disease, diabetes, anaemia, chronic renal failure, and connective tissue disease. *p<0.05. | ||||||
| Lipid lowering drugs | 121 (5.93) | 1600 (4.44) | 1.36* | (1.12 to 1.65) | 1.27* | (1.05 to 1.55) |
| Statins | 95 (4.66) | 1334 (3.70) | 1.27* | (1.02 to 1.58) | 1.22* | (1.03 to 1.45) |
| Pravastatin | 25 (1.23) | 313 (0.87) | 1.42 | (0.94 to 2.15) | 1.31 | (0.86 to 1.98) |
| Fluvastatin | 5 (0.25) | 68 (0.19) | 1.36 | (0.54 to 3.38) | 1.24 | (0.49 to 3.12) |
| Atorvastatin | 21 (1.03) | 436 (1.21) | 0.85 | (0.54 to 1.32) | 0.78 | (0.50 to 1.23) |
| Simvastatin | 49 (2.40) | 811 (2.25) | 1.05 | (0.78 to 1.42) | 1.02 | (0.76 to 1.37) |
| Fibrates | 33 (1.62) | 340 (0.94) | 1.72* | (1.19 to 2.48) | 1.54* | (1.07 to 2.23) |
| Bezafibrate | 11 (0.54) | 130 (0.36) | 1.41 | (0.75 to 2.65) | 1.29 | (0.69 to 2.42) |
| Fenofibrate | 11 (0.54) | 112 (0.31) | 1.75 | (0.94 to 3.28) | 1.56 | (0.83 to 2.92) |
| Gemfibrozil | 12 (0.59) | 141 (0.39) | 1.54 | (0.85 to 2.79) | 1.34 | (0.74 to 2.44) |
| Bile acid sequestrants | 1 (0.05) | 25 (0.07) | 0.79 | (0.11 to 5.88) | 0.55 | (0.07 to 4.20) |